These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 13750826)

  • 1. [Chemical structure and antibacterial action of isoniazid analogs].
    KAKIMOTO S; KRUEGER-THIEMER E; WEMPE E
    Arzneimittelforschung; 1960 Dec; 10():963-7. PubMed ID: 13750826
    [No Abstract]   [Full Text] [Related]  

  • 2. Antimycobacterial activity of N-isonicotinyl hydrazide and cross resistance to isoniazid.
    KLUGH GA; PRATT PC; ATWELL RJ
    Am Rev Respir Dis; 1960 Aug; 82():251-2. PubMed ID: 14410011
    [No Abstract]   [Full Text] [Related]  

  • 3. Antituberculous activity of isoniazid in combination with sulfisoxazole (Gantrisin). I. The effect of isoniazid-sulfisoxazole in vitro.
    NAITO M; WATANABE R; TSUKUMA S; IBA K
    Acta Tuberc Jpn; 1960 Sep; 10():47-56. PubMed ID: 13727549
    [No Abstract]   [Full Text] [Related]  

  • 4. [Mechanism of action & possibilities of application of isoniazid derivatives].
    IWAINSKY H; SIEGEL D
    Tuberkulosearzt; 1959 Feb; 13(2):116-22. PubMed ID: 13647677
    [No Abstract]   [Full Text] [Related]  

  • 5. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
    Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
    J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Search for new tuberculostatics. VI. Some newer derivatives of isoniazid].
    ZSOLNAI T
    Zentralbl Bakteriol Orig; 1959 Jun; 175(3-4):269-81. PubMed ID: 13669681
    [No Abstract]   [Full Text] [Related]  

  • 7. [Tuberculostatic activity of isonicotylamino-I, dimethyl-2,5, pyrrol (G.144), a structural analogue of isoniazid].
    GAZAVE JM; BUU-HOI NP; XUONG ND
    Therapie; 1957; 12(4):486-92. PubMed ID: 13467825
    [No Abstract]   [Full Text] [Related]  

  • 8. [Mode of action of isoniazid viewed from isotope incorporation studies].
    TSUKAMURA M; MIZUNO S
    Kekkaku; 1962 Jan; 37():29-35. PubMed ID: 13922899
    [No Abstract]   [Full Text] [Related]  

  • 9. 1H and 13C NMR characterization of pyridinium-type isoniazid-NAD adducts as possible inhibitors of InhA reductase of Mycobacterium tuberculosis.
    Broussy S; Bernardes-Génisson V; Coppel Y; Quémard A; Bernadou J; Meunier B
    Org Biomol Chem; 2005 Feb; 3(4):670-3. PubMed ID: 15703806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biological properties of phthivazid resistant tuberculosis strains].
    KLEBANOVA AA
    Probl Tuberk; 1958; 36(1):91-6. PubMed ID: 13554328
    [No Abstract]   [Full Text] [Related]  

  • 11. Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base.
    Hearn MJ; Cynamon MH
    J Antimicrob Chemother; 2004 Feb; 53(2):185-91. PubMed ID: 14688045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo activities of acylated derivatives of isoniazid against mycobacterium tuberculosis.
    Hearn MJ; Cynamon MH
    Drug Des Discov; 2003; 18(4):103-8. PubMed ID: 15553921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pigments produced by Mycobacteria on exposure to isoniazid. 2.
    YOUATT J
    Aust J Exp Biol Med Sci; 1962 Jun; 40():197-9. PubMed ID: 14009316
    [No Abstract]   [Full Text] [Related]  

  • 14. [Experimental studies of anti-tuberculous effect of phthivaside].
    ZEBROWSKI T; PIENIAZEK J; TROJANOWSKI S; BOROWIECKA A
    Pol Tyg Lek (Wars); 1957 Sep; 12(36):1390-3. PubMed ID: 13505232
    [No Abstract]   [Full Text] [Related]  

  • 15. [Study of the antituberculous activity of 1-(2-butenylidene)-2-isonicotinoylhydrazine].
    VIALLIER J; OLLAGNIER C; AUGAGNEUR J
    C R Seances Soc Biol Fil; 1959; 153(1):109-10. PubMed ID: 13663369
    [No Abstract]   [Full Text] [Related]  

  • 16. Rational design of new antituberculosis agents: receptor-independent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives.
    Pasqualoto KF; Ferreira EI; Santos-Filho OA; Hopfinger AJ
    J Med Chem; 2004 Jul; 47(15):3755-64. PubMed ID: 15239654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the binding of isoniazid and analogues to Mycobacterium tuberculosis catalase-peroxidase.
    Zhao X; Yu S; Magliozzo RS
    Biochemistry; 2007 Mar; 46(11):3161-70. PubMed ID: 17309235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro antituberculous activity of the dihydrostreptomycin salt of sulfoniazid (streptorilone)].
    VIALLIER J; CAYRE RM
    C R Seances Soc Biol Fil; 1958; 152(11):1501-3. PubMed ID: 13639410
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones.
    Sriram D; Yogeeswari P; Madhu K
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4502-5. PubMed ID: 16115763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.
    Vilchèze C; Wang F; Arai M; Hazbón MH; Colangeli R; Kremer L; Weisbrod TR; Alland D; Sacchettini JC; Jacobs WR
    Nat Med; 2006 Sep; 12(9):1027-9. PubMed ID: 16906155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.